United States securities and exchange commission logo





                         April 23, 2021

       Adi Mor
       Chief Executive Officer
       Chemomab Therapeutics Ltd.
       Kiryat Atidim, Building 7
       Tel Aviv 6158002, Israel

                                                        Re: Chemomab
Therapeutics Ltd.
                                                            Registration
Statement on Form S-3
                                                            Filed April 15,
2021
                                                            File No. 333-255249

       Dear Ms. Mor:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Abby
Adams at (202) 551-6902 with any questions.




                         Sincerely,


                         Division of Corporation Finance

                         Office of Life Sciences
       cc:                                              David S. Glatt